TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Entero Therapeutics ( (ENTO) ) is now available.
On August 9, 2025, Entero Therapeutics entered into a securities purchase agreement to sell pre-funded and common stock purchase warrants for approximately $3 million in a private placement. The transaction is expected to close on August 11, 2025, with proceeds intended for corporate purposes and debt repayment. The agreement includes the appointment of Geordan Pursglove and Jason Sawyer to the board of directors, effective August 11, 2025, enhancing the company’s leadership with their extensive experience in biotechnology and investment sectors.
More about Entero Therapeutics
Entero Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. Their programs address significant unmet needs in GI health and include latiglutenase for celiac disease, capeserod for gastroparesis, and adrulipase for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients.
Average Trading Volume: 1,645,705
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.74M
See more insights into ENTO stock on TipRanks’ Stock Analysis page.